Asymmetric dimethylarginine Options
Kantarjian et al53 assessed the efficacy and security of dasatinib, as in contrast with imatinib, for the main-line procedure of CML-CP. 5 hundred and nineteen individuals with freshly diagnosed CML-CP had been randomly assigned to obtain dasatinib in a dose of one hundred mg at the time each day (259 patients) or imatinib at a dose of four hundred